Ainos, a leading innovator in healthcare, is making strides with its groundbreaking AI-powered technologies and advancements in rare disease treatments. Under the visionary leadership of Chairman, President, and CEO Chun-Hsien (Eddy) Tsai, the company shared its transformative achievements and ambitious plans for the coming year in a recent letter to shareholders. The company’s dual focus on cutting-edge diagnostic solutions and low-dose interferon therapeutics has positioned it at the forefront of technological and clinical advancements.
Breaking Barriers with AI Nose Technology
Ainos has taken significant steps toward digitizing scent through its Smell ID technology, a revolutionary AI-driven platform that mimics the human sense of smell. This breakthrough enables applications in healthcare, industrial safety, and environmental monitoring.
Key Areas of Impact
- Healthcare Applications: AI Nose is unlocking new diagnostic potential by detecting volatile organic compounds (VOCs), aiding early disease detection, and enhancing monitoring capabilities for telehealth applications.
- Women’s Health: The Ainos Flora device, a game-changing innovation in STI testing, achieved a 94% accuracy rate in clinical trials. With plans to initiate trials for a second-generation model in 2025, Ainos is positioned to address the unmet needs of a global market where POCT solutions make up just 31% of STI diagnostics.
- Elder Care: AI Nose technology is tailored to meet the demands of an aging global population, starting with Japan. With one-third of its citizens aged 65 or older, Japan faces a critical shortfall in caregivers. AI-powered remote monitoring tools aim to support the nation’s nursing care systems.
- Smart Manufacturing: Collaborations with Nisshinbo Micro Devices and Itochu Techno-Solutions yielded a VOC detection platform with 80% accuracy. Mass production is slated to begin in 2025, initially targeting the semiconductor industry in Asia.
VELDONA®: Pioneering Low-Dose Interferon Therapies
Ainos continues to expand its VELDONA® platform, delivering low-dose oral interferon therapies with promising applications in human and veterinary medicine.
Ongoing and Upcoming Trials
- Sjögren’s Syndrome: Clinical trials for this chronic autoimmune disorder are set to begin in early 2025, with completion expected by 2026.
- HIV-Related Oral Warts: A study to assess VELDONA®’s efficacy in managing oral warts among HIV patients will launch in 2025, targeting trial completion in 2026.
- Veterinary Applications: Research into feline chronic gingivostomatitis (FCGS) is advancing, with results anticipated by mid-2025.
Strategic Collaborations
A partnership with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, will facilitate VELDONA® manufacturing and commercialization in Taiwan, with the goal of expanding to global markets.
Vision for 2025 and Beyond
Ainos is setting ambitious goals for the coming year, including:
- Scaling AI Nose Technology: Driving mass production for healthcare, elder care, and industrial applications, alongside advancing the second-generation Ainos Flora device.
- Progressing VELDONA® Trials: Preparing Investigational New Drug (IND) applications for submission to the U.S. FDA.
- Strengthening Partnerships: Expanding collaborations with Mitsubishi Tanabe Pharma and exploring new opportunities for AI-powered diagnostics and therapeutics.
- Enhancing Intellectual Property: Building a robust IP portfolio to secure the company’s technological edge.
Ainos remains steadfast in its mission to enhance health outcomes, promote sustainability, and improve quality of life globally. With a commitment to innovation and collaboration, the company is poised to lead the way in healthcare technology and rare disease treatments.
As the company enters 2025, it calls on shareholders and stakeholders to join its journey of transforming the future. Together, Ainos aims to create meaningful change for society and deliver groundbreaking solutions to the most pressing healthcare challenges of our time.
About Ainos, Inc.
Headquartered in San Diego, California, Ainos is a diversified healthcare company specializing in AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics. Its cutting-edge product pipeline includes AI Nose technology and VELDONA® solutions for human and animal health.
